MISSION Therapeutics
Colin Goddard serves on the board of several public and private Biotechnology companies and is Chairman and CEO of BlinkBio, Inc and is a non-executive director of Endocyte Inc. (Nasdaq: ECYT). From October 1998 until its $4 billion acquisition by Astellas Pharmaceuticals Inc. in June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals Inc, a company he joined as a scientist in 1989. Dr. Goddard has been active in many organizations that promote the advancement of cancer treatment and awareness, science education and the biotechnology industry. He received his PhD in Cancer Pharmacology in the UK in 1985.
This person is not in the org chart
This person is not in any offices
MISSION Therapeutics
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).